Want to see STIM full AI Analyst Report?
STIM Stock Chart & Stats
$3.00
$0.08(4.62%)
At close: 4:00 PM EDT
$3.00
$0.08(4.62%)
Day’s Range― - ―
52-Week Range$0.80 - $3.44
Previous Close$1.8
Volume807.96K
Average Volume (3M)1.10M
Market Cap
$153.16M
Enterprise Value$160.20M
Total Cash (Recent Filing)$19.43M
Total Debt (Recent Filing)$86.52M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Nov 04, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding76,197,220
10 Day Avg. Volume663,369
30 Day Avg. Volume1,098,509
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.07
Price to Sales (P/S)0.61
P/FCF Ratio-4.30
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue1.03
Enterprise Value/Gross Profit2.10
Enterprise Value/Ebitda-8.10
Forecast
1Y Price Target
$5.50Price Target Upside83.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$161.83M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthGrowing revenue, led by stronger Greenbrook clinic performance, indicates improving commercial traction across the company’s interventional psychiatry platform. If sustained, higher collections, payer contracting, and clinic activity can support recurring treatment revenue and improve operating leverage over the next several quarters.
Margin And Cost ImprovementThe combination of higher gross margin, lower operating expenses, and positive adjusted EBITDA shows meaningful progress toward a more sustainable operating model. These improvements can strengthen earnings quality and reduce the scale of future funding needs if management maintains cost discipline while expanding revenue.
Expanded NeuroStar Commercial ModelOffering purchase, lease-finance, and a la carte support broadens how providers can adopt NeuroStar and may reduce reliance on a single session-based model. Capital sales growth also creates additional installed-base opportunities for future service, support, and treatment-related revenue.
Bears Say
High LeverageVery high leverage limits financial flexibility and leaves the company more dependent on improved operating performance to stabilize its capitalization. The combination of substantial debt relative to equity and deeply negative returns can increase refinancing or dilution pressure if profitability does not improve.
Persistent Cash BurnContinued negative operating and free cash flow means the business has not yet demonstrated self-funded growth. Even though the burn rate improved versus earlier periods, ongoing funding needs could constrain investment and increase reliance on financing until cash generation becomes sustainably positive.
NeuroStar Utilization And Transition RiskDeclining NeuroStar revenue and treatment sessions indicate that the core platform is not yet converting its installed clinical footprint into consistent utilization growth. Underused capacity and the shift toward new purchase and lease models could prolong execution challenges and make near-term revenue development less predictable.
Neuronetics News
STIM FAQ
What was Neuronetics Inc’s price range in the past 12 months?
Neuronetics Inc lowest stock price was $0.80 and its highest was $3.44 in the past 12 months.
What is Neuronetics Inc’s market cap?
Neuronetics Inc’s market cap is $153.16M.
When is Neuronetics Inc’s upcoming earnings report date?
Neuronetics Inc’s upcoming earnings report date is Nov 04, 2026 which is in 13 days.
How were Neuronetics Inc’s earnings last quarter?
Neuronetics Inc released its earnings results on Aug 11, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.123 by $0.073.
Is Neuronetics Inc overvalued?
According to Wall Street analysts Neuronetics Inc’s price is currently Undervalued.
Does Neuronetics Inc pay dividends?
Neuronetics Inc does not currently pay dividends.
What is Neuronetics Inc’s EPS estimate?
Neuronetics Inc’s EPS estimate is -0.09.
How many shares outstanding does Neuronetics Inc have?
Neuronetics Inc has 76,197,220 shares outstanding.
What happened to Neuronetics Inc’s price movement after its last earnings report?
Neuronetics Inc reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.123. Following the earnings report the stock price went up 47.005%.
Which hedge fund is a major shareholder of Neuronetics Inc?
Currently, no hedge funds are holding shares in STIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuronetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (83.33% Upside)
$5.50 (83.33% Upside)
Blogger Sentiment
Bullish
STIM Sentiment 67%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $44.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.20%
12-Months-Change
Fundamentals
Return on Equity
-150.56%
Trailing 12-Months
Asset Growth
-2.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Neuronetics Inc
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
STIM Company Deck
STIM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed measurable operational and financial progress: revenue growth (9.1%), strong Greenbrook performance (+16.8%), margin expansion (to 51.1%), reduced OPEX (-12%), an improved net loss and a positive adjusted EBITDA, plus strengthened cash and an ATM raise. These positives were balanced against execution and timing risks centered on NeuroStar's transition (NeuroStar revenue down 2.7% and sessions down double digits due to inventory normalization and mix shifts), underused clinic capacity (~40%), potential short-term revenue choppiness as customers migrate to new purchase/lease models, and dependence on external regulatory timelines for psychedelics. On balance, the company demonstrated tangible progress toward profitability and cash generation while acknowledging near-term mix and execution challenges.View all STIM earnings summariesSTIM Stock 12 Month Forecast
Average Price Target
$5.50
▲(83.33% Upside)
Technical Analysis
Ownership Overview
28.52% Insiders
5.09% Mutual Funds
36.11% Other Institutional Investors
26.90% Public Companies and
Individual Investors